c-myc activity inhibits tumour cell immortalization and disrupts the function of CDKs, cyclins, and E2F transcription factors, and reverses the inhibitory effects of CDK p27KIP1 and p21CIP1/WAF1 [15,21]. Here, MYC is linked to neoplasm.